A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Innate lymphoid cells (ILCs) are lymphocytes that lack rearranged antigen receptors but produce cytokines mirroring T helper subsets (ILC1 → IFN-γ, ILC2 → IL-5/IL-13, ILC3 → IL-17/IL-22). ILC3s are particularly important at mucosal barriers, producing IL-22 to strengthen epithelial tight junctions and antimicrobial peptides, providing rapid innate protection before adaptive responses develop.
Contrast ILCs with T cells regarding antigen recognition and speed of response. Study ILC3 regulation of commensal bacteria and mucosal homeostasis.
ILCs are not a single cell type—they comprise multiple subsets with distinct functions. ILCs were not recently 'discovered' in humans; they exist in mice and have ancient evolutionary roots.
You are familiar with the distinction between innate and adaptive immunity: innate responses are fast but nonspecific, while adaptive responses are slow to develop but exquisitely antigen-specific thanks to rearranged receptors on T and B cells. You also know that T helper subsets (Th1, Th2, Th17) each produce distinct cytokine profiles tailored to different pathogen types. Innate lymphoid cells (ILCs) are a family of immune cells that blur the boundary between these two systems — they are lymphocytes (derived from the same precursors as T and B cells) but they lack rearranged antigen receptors, making them functionally innate. Their defining feature is that they mirror the cytokine outputs of T helper subsets without needing antigen-specific activation.
ILCs are classified into three main groups based on the transcription factors they express and the cytokines they produce — and this classification directly parallels the T helper subsets you already know. Group 1 ILCs (ILC1s) express T-bet and produce IFN-γ, just like Th1 cells, contributing to defense against intracellular pathogens and viruses. Natural killer (NK) cells are a related but distinct cytotoxic member of this group. Group 2 ILCs (ILC2s) express GATA-3 and produce IL-5 and IL-13, mirroring Th2 cells, and play roles in anti-parasite responses and allergic inflammation. Group 3 ILCs (ILC3s) express RORγt and produce IL-17 and IL-22, paralleling Th17 cells, and are critical for maintaining barrier integrity at mucosal surfaces.
ILC3s deserve special attention because of their role in barrier immunity — the defense of mucosal surfaces in the gut, lungs, and skin. ILC3-derived IL-22 acts on epithelial cells to strengthen tight junctions (the seals between epithelial cells that prevent microbial invasion), stimulate production of antimicrobial peptides (such as RegIIIγ and defensins), and promote epithelial cell proliferation for tissue repair. This means ILC3s help maintain the physical and chemical barrier that keeps commensal bacteria confined to the gut lumen and prevents pathogenic microbes from breaching into underlying tissue. Because ILCs do not require antigen-specific priming, they provide this protection within hours — long before adaptive T cell responses can develop.
The evolutionary logic of ILCs becomes clear when you consider their tissue distribution: they are tissue-resident cells concentrated at barrier surfaces where rapid responses to microbial breach are essential. While adaptive T cells take days to activate, expand, and migrate to infection sites, ILCs are already positioned at the front line, pre-loaded with the appropriate cytokine program. They act as a rapid-response force that holds the line until the adaptive immune system mobilizes. In neonates, whose adaptive immune system is still maturing, ILCs are particularly critical for maintaining mucosal homeostasis and preventing invasive infection.